Insuline signs J&J marketing deal for Germany

Insuline has developed a medical device that increases insulin absorption rates

Insuline Medical Ltd. (TASE: INSL), developer of a medical device that improves the rate of insulin absorption for diabetics, has finalized a deal with J&J (NYSE:JNJ) unit, LifeScan, Inc. Under the terms of the agreement, LifeScan will market Insulines product in Germany.

Following the announcement, the companys share price rose 6.7%, with a trading volume of NIS 10 million, triple the average amount over the past month. Insuline has a market cap of NIS 314 million.

Insuline has developed a medical device that warms the injection site, and increases the rate at which the insulin is absorbed. The faster the insulin is absorbed, the more effective it is. Currently, there are chemically-enhanced, rapid-acting insulin products on the market, but Insulines product improves the absorption rates of both rapid-acting insulin, and regular insulin.

The company chose to launch its product first in Germany, where it will serve as a pilot, and a future basis for all European markets.

Published by Globes [online], Israel business news - - on October 17, 2013

Copyright of Globes Publisher Itonut (1983) Ltd. 2013

Twitter Facebook Linkedin RSS Newsletters Israel Business Conference 2018